Fri, November 8, 2019

Alethia Young Maintained (SRPT) at Buy with Decreased Target to $185 on, Nov 8th, 2019

  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. ith-decreased-target-to-185-on-nov-8th-2019.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Alethia Young of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $201 to $185 on, Nov 8th, 2019.

Alethia has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 0 agree with Alethia's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Alethia


  • Whitney Ijem of "Guggenheim" Initiated at Strong Buy and Held Target at $183 on, Friday, November 1st, 2019
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $160 on, Friday, October 11th, 2019
  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $180 on, Friday, September 27th, 2019
  • Brian Skorney of "Baird" Maintained at Buy with Decreased Target to $181 on, Tuesday, August 20th, 2019
  • Yun Zhong of "Janney Montgomery Scott" Maintained at Strong Buy with Decreased Target to $175 on, Tuesday, August 20th, 2019